🎉 M&A multiples are live!
Check it out!
Company | Headquarters | Sector | Stock Price | Enterprise Value | EV/Revenue | EV/EBITDA |
---|---|---|---|---|---|---|
AstraZeneca | United Kingdom of Great Britain and Northern Ireland | Biopharmaceuticals, Drug Development & Therapeutics | £118 | $271B | 4.7x | 13.5x |
GSK | United Kingdom of Great Britain and Northern Ireland | Biopharmaceuticals, Drug Development & Therapeutics, Vaccines & Immunotherapies | £15 | $96.9B | 2.3x | 6.7x |
Haleon | United Kingdom of Great Britain and Northern Ireland | Health & Beauty, Drug Development & Therapeutics | £4 | $54.1B | 3.6x | 14.5x |
Hikma Pharmaceuticals | United Kingdom of Great Britain and Northern Ireland | Biopharmaceuticals, Drug Development & Therapeutics | £18 | $6.6B | 2.0x | 7.6x |
Genus | United Kingdom of Great Britain and Northern Ireland | Agriculture, Genomics & Personalized Medicine, Bioindustrials | £26 | $2.6B | 2.9x | 16.7x |
Oxford Nanopore Techs | United Kingdom of Great Britain and Northern Ireland | Pharma Diagnostics & Analytics, Medical Devices | £2 | $1.9B | 7.0x | -14.1x |
HUTCHMED | United Kingdom of Great Britain and Northern Ireland | Biopharmaceuticals, Drug Development & Therapeutics | £2 | $1.3B | 2.1x | -74.0x |
Oxford BioMedica | United Kingdom of Great Britain and Northern Ireland | Contract Research & Manufacturing, Drug Development & Therapeutics | £6 | $977M | 4.8x | -256.9x |
Allergy Therapuetics | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Vaccines & Immunotherapies | £0 | $533M | 6.8x | -21.6x |
International Biotechnology Trust | United Kingdom of Great Britain and Northern Ireland | Private Equity, Asset Management | £7 | $354M | N/A | N/A |
Avacta Group | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Pharma Diagnostics & Analytics | £1 | $345M | 6808.3x | -10.3x |
Faron Pharmaceuticals | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Vaccines & Immunotherapies | £2 | $324M | 374447.2x | -13.1x |
Animalcare Group | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics | £3 | $256M | 2.3x | 12.1x |
Bioventix | United Kingdom of Great Britain and Northern Ireland | Pharma Diagnostics & Analytics | £25 | $170M | 9.4x | 12.3x |
4basebio | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Genomics & Personalized Medicine | £9 | $158M | 55.2x | -8.3x |
Scancell | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Vaccines & Immunotherapies | £0 | $153M | 28.4x | -9.9x |
Shield Therapeutics | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics | £0 | $114M | 2.4x | -8.5x |
PureTech Health | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics, Biopharmaceuticals | £1 | $102M | 25.0x | -0.7x |
Eco Animal Health Group | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics | £1 | $38.1M | 0.3x | 3.8x |
Futura Medical | United Kingdom of Great Britain and Northern Ireland | Drug Development & Therapeutics | £0 | $27.8M | 2.6x | -11.5x |
Provexis | United Kingdom of Great Britain and Northern Ireland | Nutraceuticals & Cosmeceuticals | £0 | $22.5M | N/A | N/A |
Eden Research | United Kingdom of Great Britain and Northern Ireland | Agriculture, Bioindustrials | £0 | $17.8M | 2.8x | -10.0x |
GenIP | United Kingdom of Great Britain and Northern Ireland | Artificial Intelligence, Pharma Diagnostics & Analytics | £0 | $4.1M | N/A | N/A |
Valuation multiples as of last 12 months (LTM). Stock prices as of August 31, 2025. Financial data powered by Morningstar and FactSet.
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.